Amicus Therapeutics, Inc. (LON:0HF9)
8.24
-0.19 (-2.24%)
At close: Oct 10, 2025
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $154.69M USD in the quarter ending June 30, 2025, with 22.12% growth. This brings the company's revenue in the last twelve months to $571.16M, up 25.35% year-over-year. In the year 2024, Amicus Therapeutics had annual revenue of $528.30M with 32.29% growth.
Revenue (ttm)
$571.16M
Revenue Growth
+25.35%
P/S Ratio
4.54
Revenue / Employee
$1.14M
Employees
499
Market Cap
1.89B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 528.30M | 128.94M | 32.29% |
Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Amicus Therapeutics News
- 24 days ago - Interesting FOLD Put And Call Options For November 21st - Nasdaq
- 25 days ago - Amicus Therapeutics (FOLD) Upgraded by Needham with Increasing Sales Potential - GuruFocus
- 25 days ago - Amicus upgraded to Buy at Needham banking on kidney disease therapy - Seeking Alpha
- 25 days ago - Amicus (FOLD) Sees Favorable Upgrade Following Regulatory Developments - GuruFocus
- 25 days ago - FOLD: Needham Upgrades Amicus Therapeutics to Buy with $14 Target | FOLD Stock News - GuruFocus
- 25 days ago - This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
- 4 weeks ago - Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 5 weeks ago - Amicus (FOLD) Reveals Positive 4-Year Results for Pompe Disease Treatment - GuruFocus